Evidence map›Paper›PMID 33778324›Full record

ArticleJBMR plus2021

Resveratrol Reduces COMPopathy in Mice Through Activation of Autophagy.

Jacqueline T Hecht, Francoise Coustry, Alka C Veerisetty, Mohammad G Hossain, Karen L Posey

Abstract read
In one paragraph

Article in JBMR plus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. "Lessons from Rare Forms of Osteoarthritis".Calcified tissue international · 2021
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jacqueline T HechtDepartment of Pediatrics, McGovern Medical School The University of Texas Health Science Center at Houston (UTHealth) Houston TX USA.
Francoise CoustryDepartment of Pediatrics, McGovern Medical School The University of Texas Health Science Center at Houston (UTHealth) Houston TX USA.ORCID https://orcid.org/0000-0001-9686-6121
Alka C VeerisettyDepartment of Pediatrics, McGovern Medical School The University of Texas Health Science Center at Houston (UTHealth) Houston TX USA.
Mohammad G HossainDepartment of Pediatrics, McGovern Medical School The University of Texas Health Science Center at Houston (UTHealth) Houston TX USA.
Karen L PoseyDepartment of Pediatrics, McGovern Medical School The University of Texas Health Science Center at Houston (UTHealth) Houston TX USA.ORCID https://orcid.org/0000-0003-1234-6087

Funding

Consequences of Mutant COMP Expression and Therapeutic Approaches in Transgenic MiceR01AR057117 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HECHT, JACQUELINE T, POSEY, KAREN LASHEA · 2010 to 2020
$4.2M
NIAMS NIH HHS R01 AR057117
6 · The paper itself

Abstract

Misfolding mutations in cartilage oligomeric matrix protein (COMP) cause it to be retained within the endoplasmic reticulum (ER) of chondrocytes, stimulating a multitude of damaging cellular responses including ER stress, inflammation, and oxidative stress, which ultimately culminates in the death of growth plate chondrocytes and pseudoachondroplasia (PSACH). Previously, we demonstrated that an antioxidant, resveratrol, substantially reduces the intracellular accumulation of mutant-COMP, dampens cellular stress, and lowers the level of growth plate chondrocyte death. In addition, we showed that resveratrol reduces mammalian target of rapamycin complex 1 (mTORC1) signaling, suggesting a potential mechanism. In this work, we investigate the role of autophagy in treatment of COMPopathies. In cultured chondrocytes expressing wild-type COMP or mutant-COMP, resveratrol significantly increased the number of Microtubule-associated protein 1A/1B-light chain 3 (LC3) vesicles, directly demonstrating that resveratrol-stimulated autophagy is an important component of the resveratrol-driven mechanism responsible for the degradation of mutant-COMP. Moreover, pharmacological inhibitors of autophagy suppressed degradation of mutant-COMP in our established mouse model of PSACH. In contrast, blockage of the proteasome did not substantially alter resveratrol clearance of mutant-COMP from growth plate chondrocytes. Mechanistically, resveratrol increased SIRT1 and PP2A expression and reduced MID1 expression and activation of phosphorylated protein kinase B (pAKT) and mTORC1 signaling in growth plate chondrocytes, allowing clearance of mutant-COMP by autophagy. Importantly, we show that optimal reduction in growth plate pathology, including decreased mutant-COMP retention, decreased mTORC1 signaling, and restoration of chondrocyte proliferation was attained when treatment was initiated between birth to 1 week of age in MT-COMP mice, translating to birth to approximately 2 years of age in children with PSACH. These results clearly demonstrate that resveratrol stimulates clearance of mutant-COMP by an autophagy-centric mechanism. © 2020 The Authors.

Indexed as

DISEASES AND DISORDERS OF/RELATED TO BONEGENETIC ANIMAL MODELSGROWTH PLATEPRECLINICAL STUDIESTHERAPEUTICS

Identifiers

PMID33778324
PMCPMC7990140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.